Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults
NCT ID: NCT01143623
Last Updated: 2011-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
510 participants
INTERVENTIONAL
2010-05-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms
NCT05845073
Mechanisms of Probiotics and Antibiotic-Associated Diarrhea
NCT04414722
Effect of Probiotics on the Digestibility and Immunity in Infants
NCT02317406
Effect of Probiotic on the Gut Microbiota of Healthy Volunteers
NCT06103253
Shanghai Infants Gut Microbiome Associated Study
NCT03388112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Probiotic
L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
Probiotic-2
Probiotic
L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
Probiotic
L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* initiating antibiotic therapy
* informed consent
Exclusion Criteria
* life threatening illness
* habitual probiotic use
30 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cai DongLian
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-SBC-2-DAN-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.